Dr. Mungall leads teams of skilled genome science technologists, research assistants and supervisors in procuring and processing diverse biological samples for next generation sequencing clinical and research applications.
Dr. Mungall was a founding member of the human genome sequencing group at the Wellcome Trust Sanger Institute (formerly the Sanger Centre, Cambridge, UK) and subsequently led the mapping and sequencing of human chromosome 6. He received a PhD from the Open University and Wellcome Trust Sanger Institute in 2008 for studies on the evolution and gene regulation of the genomic imprinting mechanism. He currently holds a Staff Scientist II post and is the Group Leader for Biospecimen and Library Cores at Canada’s Michael Smith Genome Sciences Centre (GSC) of BC Cancer in Vancouver. Previous roles included the scientific leadership of The Cancer Genome Atlas project at the GSC and current interests include the application of ‘omics’ technologies in clinical research. Dr. Munall has a leadership role in the Centre for Clinical Genomics (CCG) at the GSC, providing cancer assays to thousands of BC residents every year. For this work the CCG won the 2014 Gold Apple Award for the BC Health Care Top Innovation. Other areas of research focus on the identification of tumour genome rearrangements and mutations in leukemias and lymphomas. For this work Andy has been honoured with the David Rae Memorial and Journey of Hope Awards by the Leukemia & Lymphoma Society of Canada.
Andy has presented his work at 80 national and international conferences and was named a Highly Cited Researcher in 2018 and 2019 by Web of Science having ~70,000 citations to over 200 peer-reviewed scientific publications. He is an associate editor of Genomic Assay Technology for open access journals Frontiers in Genetics & Frontiers in Bioengineering and Biotechnology.
Co-investigator, Canadian Cancer Society Research Institute Innovation to Impact grant (Aug 2016-July 2019, $449,997 CAD).
Co-investigator, The Terry Fox New Frontiers Program Project Grant (July 2016 – June 2021, $7,500,000 CAD)